Study guide

20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care

Key Takeaways Explain This Topic AI

Transitions of care are the highest-risk moments in addiction treatment, with sharply elevated overdose mortality in the first two weeks after release from incarceration and after discharge from residential or inpatient treatment.

Warm handoffs, in which the referring clinician introduces the patient directly to the receiving clinician, substantially outperform giving the patient a phone number.

Medication for opioid use disorder started in the hospital or emergency department and linked to outpatient care increases treatment engagement compared with referral alone.

A bridge prescription covering the gap between discharge and the first outpatient appointment prevents the most common cause of post-discharge treatment failure.

Care coordination requires an explicit division of prescribing responsibility so that no two clinicians are independently managing the same controlled substance.

Last updated: September 2026

20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care

Quick Answer: Transitions kill. Overdose mortality is sharply elevated in the first two weeks after release from incarceration and after discharge from residential or inpatient treatment, because tolerance falls while access and cues return. The interventions that work are concrete: initiate medication before the transition , warm handoff rather than a phone number, bridge prescription covering the gap to the first appointment, naloxone in hand at the moment of transition , and an explicit division of prescribing responsibility so no controlled substance has two independent prescribers.

1. The Transition Points That Matter

Transition Dominant risk Countermeasure

Jail or prison release Tolerance loss; loss of housing, insurance and identification Start or continue medication in custody; naloxone at the gate; appointment within 72 hours; Medicaid reinstatement arranged in advance

Residential or inpatient discharge Tolerance loss; abrupt drop in structure Medication started before discharge; first outpatient contact within days, not weeks

Emergency department discharge after overdose Highest-risk population, lowest-engagement setting Buprenorphine initiation in the ED, take-home naloxone, peer navigator contact at bedside

Hospital discharge on methadone or buprenorphine Discontinuity because retail pharmacies cannot dispense methadone for OUD Confirm the OTP will accept and has the dose; arrange the first dosing day; never assume

Obstetric to postpartum Insurance loss, custody fear, relapse peak months after delivery Postpartum plan written before delivery; explicit coverage continuity check

Detoxification to ongoing care Withdrawal management alone increases overdose death Never discharge from withdrawal management without medication and a scheduled linkage

2. Warm Handoffs

A warm handoff is a direct, real-time introduction of the patient to the receiving clinician, ideally in the patient's presence and with the patient participating.

  • Weakest to strongest
  • A phone number on a discharge sheet
  • A faxed referral
  • An appointment scheduled by staff
  • A phone call to the receiving clinician with the patient present
  • The receiving clinician or peer navigator coming to the bedside before discharge

The practical difference is large. Every additional step the patient must complete alone — call, navigate a phone tree, arrange transport, complete intake paperwork — sheds a substantial fraction of patients, and the patients lost are the ones with the least recovery capital and the highest risk.

3. Bridge Prescriptions and Medication Continuity

Bridge prescription: a short buprenorphine supply covering the interval from discharge to the first outpatient visit. Without it, a patient discharged Friday with a Tuesday appointment faces four days in withdrawal, and most will use.

Methadone is different. Retail pharmacies cannot dispense methadone for opioid use disorder. A hospitalized patient on OTP methadone must have the dose verified with the OTP and the first post-discharge dosing day confirmed , or they will be in withdrawal the next morning. Guest dosing arrangements must be made in advance.

Extended-release products: confirm timing. A patient due for Sublocade or Vivitrol during an inpatient stay should receive it before discharge rather than being told to arrange it.

Medication reconciliation must explicitly capture buprenorphine, methadone, naltrexone and naloxone, which are frequently omitted from discharge lists because they are recorded in a separate system or omitted out of stigma.

4. Dividing Responsibility Explicitly

The most common coordination failure in addictions practice is ambiguous prescribing responsibility . Rules that prevent it:

One prescriber per controlled substance. Name that person in the shared plan.

Write the division down in the chart, in language another clinician can act on: "Addiction APRN manages buprenorphine and naloxone; primary care manages hypertension and diabetes; pain clinic manages gabapentin and duloxetine and will not prescribe opioids."

Check the PDMP before each controlled prescription , which catches duplication before it becomes a diversion or overdose event.

Agree on who responds to unexpected toxicology results and what the response will be, in advance.

Name the point of contact for after-hours questions.

5. Working With Peer Recovery Specialists

Peer recovery specialists are people with lived experience of substance use disorder, trained and often state-certified, who provide engagement, navigation and support. The blueprint names them explicitly in Activity Area IV.

They reach people clinicians cannot. Emergency department peer programs substantially improve treatment engagement after overdose.

Role clarity protects everyone. Peers provide support, navigation, modeling and advocacy; they do not diagnose, prescribe, or perform clinical assessment.

Supervision and boundaries matter. Peers carry a dual relationship risk and need structured supervision, clear disclosure norms and protection from being used as unlicensed case managers.

Confidentiality applies to peers too. Peers working within a Part 2 program are bound by the same disclosure rules.

6. What Good Coordination Looks Like in the Record

A shared plan that survives handoffs contains: the diagnosis and severity; the current medication with dose and the named prescriber; the next scheduled contact with date, time and address; the naloxone status; the patient's stated goal; the specific risks flagged (pregnancy, cardiac, hepatic, concurrent sedatives); who to call; and what the escalation trigger is. Every one of these is a documented element the practice analysis rates highly under "documents communication, rationales for changes, and collaborative discussions in the plan of care to improve outcomes."